Last reviewed 2026-05-21 · How we verify

Benzylsulfanilamide (BENZYLSULFAMIDE)

Phase 2 active Small molecule ✓ Verified May 2026

Benzylsulfanilamide (generic name: BENZYLSULFAMIDE) is a benzylsulfamide drug. It is currently in Phase 2 development.

Benzylsulfanilamide works by inhibiting the enzyme carbonic anhydrase 9, which is involved in the growth and spread of cancer cells.

Benzylsulfanilamide is a small molecule. Its mechanism of action is not specified in the provided information.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 2 attrition -2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BENZYLSULFAMIDE
Drug class	benzylsulfamide
Target	Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 2
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 2

Mechanism of action

Think of carbonic anhydrase 9 like a construction crew that helps build new roads for cancer cells to grow and spread. By blocking this crew, benzylsulfanilamide can slow down the growth of tumors and prevent them from spreading to other parts of the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Benzylsulfanilamide CI brief — competitive landscape report
Benzylsulfanilamide updates RSS · CI watch RSS

Frequently asked questions about Benzylsulfanilamide

What is Benzylsulfanilamide?

Benzylsulfanilamide (BENZYLSULFAMIDE) is a benzylsulfamide drug.

How does Benzylsulfanilamide work?

Benzylsulfanilamide works by inhibiting the enzyme carbonic anhydrase 9, which is involved in the growth and spread of cancer cells.

What is the generic name of Benzylsulfanilamide?

BENZYLSULFAMIDE is the generic (nonproprietary) name of Benzylsulfanilamide.

What drug class is Benzylsulfanilamide in?

Benzylsulfanilamide belongs to the benzylsulfamide class. See all benzylsulfamide drugs at /class/benzylsulfamide.

What development phase is Benzylsulfanilamide in?

Benzylsulfanilamide is in Phase 2.

What does Benzylsulfanilamide target?

Benzylsulfanilamide targets Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 2 and is a benzylsulfamide.

Drug class: All benzylsulfamide drugs
Target: All drugs targeting Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 2
Therapeutic area: All drugs in Oncology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing